Last reviewed · How we verify
NCT05664802: e-HERO
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
NA trial testing e-HERO: Ending the HIV Epidemic in Rural Oklahoma in Human Immunodeficiency Virus (HIV) in 200 participants. Completed in 19 June 2024.
19 June 2024
Quick facts
| Lead sponsor | Northern Arizona University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 200 |
| Start date | 1 December 2022 |
| Primary completion | 19 June 2024 |
| Estimated completion | 19 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Conditions studied
- Human Immunodeficiency Virus (HIV) — all drugs for Human Immunodeficiency Virus (HIV) →
Sponsor
Northern Arizona University
Who can join
Adults 17 to 29, male only, with Human Immunodeficiency Virus (HIV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the e-HERO intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05664802
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Immunodeficiency Virus (HIV)
Currently open trials in the same condition.
- NCT07071623 — A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) · Phase 3 · recruiting
- NCT07418385 — Voluntary HIV Screening in the General Population in France · recruiting
- NCT07044297 — A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) · Phase 3 · recruiting
- NCT06814275 — Project neuroARTEMIS · NA · recruiting
- NCT06880705 — The Trans-Led Care Study · NA · recruiting
Other Northern Arizona University trials
Trials by the same sponsor.
- NCT07452094 — What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise? · EARLY_PHASE1 · not yet recruiting
- NCT07519629 — Training Caregivers to Teach Vocabulary to Children With Language Impairment · NA · recruiting
- NCT06872762 — Effect of Exercise and Heat Stress on Acute Cardiometabolic Adaptations in Healthy Young Adults · NA · recruiting
- NCT06254924 — Qoyangnuptu: Qoyangnuptu Intervention (QI) App · NA · recruiting
- NCT07176481 — Diné Parents Taking Action Trial · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05664802 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northern Arizona University
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05664802.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing